OPTN Stock Price, Optinose Inc Quote, Chart

Market Summary

USD1.26-0.03

Delayed

-2.33%

OPTN Stock Price

View Fullscreen

OPTN RSI Chart

OPTN Valuation

Market Cap

142.4M

Price/Earnings (Trailing)

-4.64

Price/Sales (Trailing)

1.92

Price/Free Cashflow

-4.39

OPTN Price/Sales (Trailing)

OPTN Profitability

Return on Equity

30.95%

Return on Assets

-36.68%

Free Cashflow Yield

-22.77%

OPTN Fundamentals

OPTN Revenue

Revenue (TTM)

74.0M

Rev. Growth (Yr)

25.61%

Rev. Growth (Qtr)

-25.09%

OPTN Earnings

Earnings (TTM)

-30.7M

Earnings Growth (Yr)

25.36%

Earnings Growth (Qtr)

-41.13%

Breaking Down OPTN Revenue

Last 7 days

3.3%

Last 30 days

23.5%

Last 90 days

-8.0%

Trailing 12 Months

-29.6%

How does OPTN drawdown profile look like?

OPTN Financial Health

Current Ratio

2.48

Debt/Equity

-1.32

Debt/Cashflow

-0.25

OPTN Investor Care

Shares Dilution (1Y)

0.97%

Diluted EPS (TTM)

-0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	74.0M	0	0	0
2023	73.4M	72.2M	72.0M	71.0M
2022	77.5M	79.7M	77.9M	76.3M
2021	54.0M	62.1M	68.5M	74.7M
2020	40.3M	35.5M	38.6M	49.1M
2019	10.7M	16.1M	29.2M	39.9M
2018	31.3M	23.2M	15.2M	7.1M
2017	0	0	0	39.4M
2016	0	0	0	47.5M
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Optinose Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	krick anthony j	sold	-4,408	1.88	-2,345	chief accounting officer
Mar 18, 2024	marino michael f iii	sold	-28,310	1.88	-15,059	chief legal officer & corp sec
Mar 18, 2024	mahmoud ramy a	sold	-36,092	1.88	-19,198	chief executive officer
Mar 15, 2024	mahmoud ramy a	acquired	-	-	6,114	chief executive officer
Mar 15, 2024	marino michael f iii	acquired	-	-	3,816	chief legal officer & corp sec
Feb 28, 2024	mahmoud ramy a	acquired	-	-	795,975	chief executive officer
Feb 28, 2024	krick anthony j	acquired	-	-	112,500	chief accounting officer
Feb 28, 2024	marino michael f iii	acquired	-	-	280,000	chief legal officer & corp sec
Feb 28, 2024	spence paul jr.	acquired	-	-	252,675	chief commercial officer
Jan 31, 2024	mahmoud ramy a	sold	-69,266	1.31	-52,875	chief executive officer

Which funds bought or sold OPTN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Garner Asset Management Corp	sold off	-100	-324	-	-%
May 16, 2024	Arete Wealth Advisors, LLC	sold off	-100	-12,900	-	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-78,891	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-4,779	10,702	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-38.23	-3,433	7,979	-%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-60.69	-4,506,580	3,612,470	0.21%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	added	33.33	177,300	525,600	0.03%
May 15, 2024	Mariner, LLC	reduced	-62.9	-25,573	18,508	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	449,115	449,115	-%
May 15, 2024	GREAT POINT PARTNERS LLC	reduced	-0.61	1,424,500	12,828,000	2.00%

Are Funds Buying or Selling OPTN?

Are funds buying OPTN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OPTN

No. of Funds

Unveiling Optinose Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	5.14%	4,541,489	SC 13G/A
Feb 22, 2024	rosalind advisors, inc.	4.4%	4,885,580	SC 13G/A
Feb 14, 2024	rosalind advisors, inc.	5.2%	479,990	SC 13G/A
Feb 14, 2024	great point partners llc	9.99%	11,484,120	SC 13G/A
Feb 13, 2024	acorn bioventures, l.p.	4.4%	5,067,698	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	kruttschnitt theodore h iii	7.98%	9,105,789	SC 13G/A
Jan 30, 2024	avista capital partners ii gp, llc	0%	0	SC 13G/A
Jul 28, 2023	rosalind advisors, inc.	5.8%	6,435,000	SC 13G
Feb 14, 2023	mvm partners, llc	14.9%	16,710,526	SC 13D/A

Recent SEC filings of Optinose Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 09, 2024	424B5	Prospectus Filed
May 09, 2024	424B5	Prospectus Filed
May 09, 2024	424B5	Prospectus Filed
May 09, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Optinose Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Optinose Inc News

Latest updates

Optinose Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q3	2019Q2
Revenue	-25.1%	14,880,000	19,864,500	19,823,000	19,454,000	11,846,000	20,856,000	20,078,000	20,582,000	14,760,000	22,509,000	21,826,000	18,357,000	11,960,000	16,347,000	15,436,000	10,272,000	7,062,000	5,819,000	12,397,000	15,000,000	6,677,000
Costs and Expenses	2.6%	22,955,000	22,377,500	21,517,000	23,626,000	26,214,000	29,212,000	30,878,000	35,927,000	36,155,000	34,175,000	34,866,000	37,912,000	34,149,000	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	34,866,000	37,912,000	34,149,000	-	33,320,000	32,871,000	33,348,000	-	32,206,000	-	32,384,000
S&GA Expenses	8.2%	20,518,000	18,960,500	18,011,000	20,104,000	22,723,000	23,310,000	25,486,000	29,514,000	29,339,000	26,340,000	25,801,000	27,308,000	27,184,000	28,106,000	24,575,000	25,697,000	27,060,000	26,545,000	25,270,000	-	26,000,000
R&D Expenses	-6.2%	1,206,000	1,286,000	1,281,000	951,000	1,785,000	2,921,000	3,267,000	4,270,000	4,802,000	5,260,000	6,654,000	8,179,000	5,225,000	6,448,000	6,524,000	5,474,000	4,932,000	5,379,000	5,547,000	-	5,295,000
EBITDA Margin	-	-	-	-	-	-	-	-	-0.82	-0.85	-0.88	-	-	-1.56	-1.74	-2.21	-2.40	-2.65	-2.87	-3.61	-5.98	-5.98
Interest Expenses	-2.4%	4,970,000	5,092,000	4,940,000	4,824,000	4,672,000	4,477,500	4,207,000	4,086,000	4,073,000	4,013,500	4,072,000	4,012,000	3,876,000	3,502,000	3,350,000	3,293,000	2,863,000	2,474,500	2,372,000	-	2,389,000
EBT Margin	-	-	-	-	-	-	-	-	-1.03	-1.06	-1.10	-	-	-1.85	-2.03	-2.51	-2.70	-2.96	-3.18	-4.01	-6.63	-6.63
Net Income	-41.1%	-14,067,000	-9,967,500	-9,294,000	2,626,000	-18,847,000	-15,149,000	-14,954,000	-19,397,000	-25,333,000	-15,624,000	-17,117,000	-23,502,000	-26,053,000	-23,863,000	-21,214,000	-25,852,000	-28,856,000	-24,995,000	-28,808,000	-	-27,376,000
Net Income Margin	17.0%	-0.41	-0.50	-0.56	-0.64	-0.93	-0.98	-0.97	-0.97	-1.05	-1.10	-1.32	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-422.5%	-22,047,000	6,836,000	-4,601,000	-12,617,000	-10,478,000	-17,683,000	-17,508,000	-13,140,000	-19,383,000	-16,740,000	-9,729,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-22.3%	84.00	108	101	106	115	144	105	123	134	166	132	140	158	189	181	153	174	173	149	167	193
Current Assets	-23.0%	81.00	105	99.00	104	112	140	101	118	128	160	125	133	150	181	172	149	170	168	144	161	187
Cash Equivalents	-29.9%	52.00	74.00	67.00	71.00	84.00	94.00	61.00	78.00	91.00	111	84.00	94.00	116	144	143	125	149	147	126	144	171
Inventory	28.1%	10.00	8.00	8.00	8.00	8.00	9.00	10.00	11.00	11.00	12.00	13.00	13.00	13.00	9.00	9.00	6.00	6.00	3.00	4.00	4.00	6.00
Net PPE	-7.5%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00
Liabilities	-5.9%	183	194	179	176	189	201	179	184	179	188	183	177	175	182	153	140	139	111	105	98.00	101
Current Liabilities	-81.5%	33.00	177	164	164	166	179	178	55.00	50.00	59.00	54.00	47.00	45.00	52.00	43.00	35.00	34.00	36.00	30.00	24.00	27.00
Long Term Debt	-	131	-	-	-	-	-	-	127	127	126	127	126	126	125	105	105	105	75.00	74.00	73.00	73.00
LT Debt, Current	-100.0%	-	130	130	129	129	129	128	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	126	-	-	-	125	-	-	-	75.00	-	-	-
Shareholder's Equity	-14.6%	-99.22	-86.61	-	-	-73.79	-56.62	-	-	-	-	-	-	-	7.00	28.00	13.00	35.00	62.00	45.00	68.00	92.00
Retained Earnings	-2.0%	-734	-720	-710	-701	-703	-684	-669	-654	-635	-610	-594	-577	-553	-527	-503	-482	-456	-427	-402	-374	-346
Additional Paid-In Capital	0.2%	635	634	633	631	630	628	596	594	591	588	543	540	537	535	532	495	492	490	448	443	439
Shares Outstanding	0.6%	113	112	112	112	112	111	83.00	83.00	82.00	82.00	53.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	119	-	-	-	202	-	-	-	95.00	-	-	-	176	-	-	-	174	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-418.8%	-22,025	6,909	-4,425	-12,538	-10,478	-17,680	-17,498	-13,138	-19,335	-16,716	-9,701	-22,494	-28,024	-19,156	-15,532	-23,550	-27,968	-18,106	-15,127	-27,888	-29,694
Share Based Compensation	48.7%	1,456	979	1,195	1,501	1,523	1,486	1,947	3,447	1,997	1,976	2,684	2,733	2,610	2,492	2,625	2,772	2,460	2,308	2,435	2,695	2,422
Cashflow From Investing	69.9%	-22.00	-73.00	-176	-79.00	-	-3.00	-10.00	-2.00	-48.00	-24.00	-28.00	81.00	-91.00	-86.00	-151	-239	-70.00	-72.00	-62.00	-255	-168
Cashflow From Financing	75.0%	7.00	4.00	135	-1.00	162	50,787	373	27.00	249	43,009	35.00	347	-71.00	20,308	33,552	572	29,378	39,831	-3,283	793	188

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OPTN Income Statement

2024-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 14,880	$ 11,846
Costs and expenses:
Cost of product sales	1,231	1,706
Research and development	1,206	1,785
Selling, general and administrative	20,518	22,723
Total costs and expenses	22,955	26,214
Loss from operations	(8,075)	(14,368)
Other (income) expense:
Unrealized loss on fair value of warrants	1,300	510
Interest income	(296)	(705)
Interest expense	4,970	4,672
Foreign currency loss	18	2
Net loss	$ (14,067)	$ (18,847)
Net loss per share of common stock, basic (in dollars per share)	$ (0.12)	$ (0.17)
Net loss per share of common stock, diluted (in dollars per share)	$ (0.12)	$ (0.17)
Weighted average common shares outstanding, basic (in shares)	112,594,852	111,774,425
Weighted average common shares outstanding, diluted (in shares)	112,594,852	111,774,425
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Net product revenues	Net product revenues
Net product revenues
Total revenues	$ 14,880	$ 11,846

OPTN Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 51,644	$ 73,684
Accounts receivable, net	14,227	19,926
Inventory	10,315	8,052
Prepaid expenses and other current assets	4,936	3,671
Total current assets	81,122	105,333
Property and equipment, net	754	815
Other assets	1,831	1,581
Total assets	83,707	107,729
Current liabilities:
Accounts payable	1,912	3,886
Accrued expenses and other current liabilities	30,793	42,411
Short term debt, net	0	130,227
Total current liabilities	32,705	176,524
Long term debt, net	130,653	0
Warrant liability	18,500	17,200
Other liabilities	1,065	611
Total liabilities	182,923	194,335
Stockholders' deficit
Preferred stock, no par value; 5,000,000 shares authorized; no shares issued in 2024 or 2023	0	0
Common stock, $0.001 par value; 350,000,000 shares authorized; 113,038,726 and 112,399,495 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.	113	112
Additional paid-in capital	635,198	633,742
Accumulated deficit	(734,443)	(720,376)
Accumulated other comprehensive loss	(84)	(84)
Total stockholders' deficit	(99,216)	(86,606)
Total liabilities and stockholders' deficit	$ 83,707	$ 107,729

About Optinose Inc

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

CEO	Dr. Ramy A. Mahmoud M.D., M.P.H.
WEBSITE	optinose.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	141

Optinose Inc Frequently Asked Questions

What is the ticker symbol for Optinose Inc? What does OPTN stand for in stocks?

OPTN is the stock ticker symbol of Optinose Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Optinose Inc (OPTN)?

As of Fri May 17 2024, market cap of Optinose Inc is 142.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPTN stock?

You can check OPTN's fair value in chart for subscribers.

What is the fair value of OPTN stock?

You can check OPTN's fair value in chart for subscribers. The fair value of Optinose Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Optinose Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OPTN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Optinose Inc a good stock to buy?

The fair value guage provides a quick view whether OPTN is over valued or under valued. Whether Optinose Inc is cheap or expensive depends on the assumptions which impact Optinose Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPTN.

What is Optinose Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OPTN's PE ratio (Price to Earnings) is -4.64 and Price to Sales (PS) ratio is 1.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPTN PE ratio will change depending on the future growth rate expectations of investors.